BPC 157 Peptide Promotes Healing of Severe Intestinal Fistulas in Rats

Duodenocolic fistulas are devastating complications, often arising from severe inflammatory bowel disease, trauma, or surgery, where an abnormal connection forms between the duodenum (first part of the small intestine) and the colon (large intestine). These fistulas lead to severe malabsorption, infection, and significant morbidity, posing immense challenges for treatment. Current therapies are often invasive and carry high failure rates. This study specifically investigated whether the stable gastric pentadecapeptide BPC 157 could effectively promote the healing of experimentally induced duodenocolic fistulas in a rat model.

Treatment with BPC 157 significantly accelerated the healing process of duodenocolic fistulas compared to control groups, demonstrating robust regenerative capabilities. Macroscopic evaluation revealed that BPC 157-treated rats showed complete fistula closure in an impressive 80% of cases, whereas the control group exhibited only 20% closure, a statistically highly significant difference (p<0.001). Histopathological analysis further demonstrated a 2.5-fold increase in organized granulation tissue formation and a 43% reduction in inflammatory cell infiltration at the fistula site in the BPC 157 group compared to controls (p<0.01), indicating reduced inflammation and enhanced tissue repair. The most striking finding was a 75% reduction in fistula diameter in BPC 157-treated rats compared to controls, signifying substantial structural repair and tissue regeneration. Furthermore, BPC 157 treatment led to a significant upregulation of key pro-angiogenic factors like VEGF (Vascular Endothelial Growth Factor, a protein that promotes new blood vessel growth) and eNOS (endothelial Nitric Oxide Synthase, an enzyme crucial for blood vessel dilation and repair) expression by 50% and 60% respectively, suggesting enhanced blood vessel formation critical for effective healing.